Abstract
Ovarian cancer accounts for more deaths than any other gynecologic malignancy. According to the Ovarian Cancer National Alliance, overall mortality rates due to ovarian cancer have not significantly improved in 40 years, a statistic that highlights the need for innovative treatment strategies. Immune checkpoint inhibitors are part of an emerging immunotherapeutic model that seeks to “inhibit the inhibitors” of adequate cancer immunosurveillance. Immune checkpoints encompass a variety of inhibitory pathways that downregulate an immune response, which allows them to assume an important physiologic role in maintaining homeostasis. While cancer cells are adept at utilizing these pathways to their advantage, basic scientists, translational researchers, and clinical trialists are making great strides in this area of investigation. This review article will focus on the development of anti-CTLA-4 and anti-PD1 monoclonal antibodies, their current role in the treatment of advanced stage EOC, and recently published patents that incorporate the use of immune checkpoint inhibition in the treatment of cancer.
Keywords: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), immune checkpoint, immunoediting, ipilimumab, nivolumab, ovarian cancer, pembrolizumab, programmed cell death protein 1 (PD-1).
Recent Patents on Anti-Cancer Drug Discovery
Title:Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer
Volume: 10 Issue: 2
Author(s): Teresa C. Longoria and Ramez N. Eskander
Affiliation:
Keywords: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), immune checkpoint, immunoediting, ipilimumab, nivolumab, ovarian cancer, pembrolizumab, programmed cell death protein 1 (PD-1).
Abstract: Ovarian cancer accounts for more deaths than any other gynecologic malignancy. According to the Ovarian Cancer National Alliance, overall mortality rates due to ovarian cancer have not significantly improved in 40 years, a statistic that highlights the need for innovative treatment strategies. Immune checkpoint inhibitors are part of an emerging immunotherapeutic model that seeks to “inhibit the inhibitors” of adequate cancer immunosurveillance. Immune checkpoints encompass a variety of inhibitory pathways that downregulate an immune response, which allows them to assume an important physiologic role in maintaining homeostasis. While cancer cells are adept at utilizing these pathways to their advantage, basic scientists, translational researchers, and clinical trialists are making great strides in this area of investigation. This review article will focus on the development of anti-CTLA-4 and anti-PD1 monoclonal antibodies, their current role in the treatment of advanced stage EOC, and recently published patents that incorporate the use of immune checkpoint inhibition in the treatment of cancer.
Export Options
About this article
Cite this article as:
Longoria C. Teresa and Eskander N. Ramez, Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (2) . https://dx.doi.org/10.2174/1574892810666150504121000
DOI https://dx.doi.org/10.2174/1574892810666150504121000 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design A Short Review on the Synthetic Strategies of Duocarmycin Analogs that are Powerful DNA Alkylating Agents
Anti-Cancer Agents in Medicinal Chemistry Chemotherapeutic Targeting of Cell Death Pathways
Anti-Cancer Agents in Medicinal Chemistry Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Telomeres, Genomic Instability, DNA Repair and Breast Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Studies on Synthesis, Activity and Binding with DNA of a New Trinuclear Platinum Compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)6 NH2}2]Cl3(NO3)
Medicinal Chemistry In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells
Current Pharmaceutical Biotechnology Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Hybrid Compounds as Multitarget Directed Anticancer Agents
Current Topics in Medicinal Chemistry MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Management of Unusual Not Scar Ectopic Pregnancy: A Multicentre Retrospective Case Series
Current Women`s Health Reviews